Last reviewed 2026-05-23 · How we verify

Trichloroisocyanuric Acid (SYMCLOSENE)

Phase 2 active Small molecule ✓ Verified May 2026

Trichloroisocyanuric Acid (generic name: SYMCLOSENE) is a drug. It is currently in Phase 2 development.

Trichloroisocyanuric Acid works by releasing chlorine gas when it comes into contact with water, which then kills bacteria and other microorganisms.

Trichloroisocyanuric acid is a small molecule compound with the synonyms SINCLOSENO, SYMCLOSENE, and TRICHLOROISOCYANURIC ACID. It is a chemical compound with the modality of a small molecule.

Likelihood of approval

17.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	SYMCLOSENE
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Think of it like a strong bleach that releases chlorine gas when it gets wet. This chlorine gas is what actually kills the bad germs and bacteria. It's like a powerful cleaning agent that helps get rid of germs and make things clean.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Trichloroisocyanuric Acid CI brief — competitive landscape report
Trichloroisocyanuric Acid updates RSS · CI watch RSS

Frequently asked questions about Trichloroisocyanuric Acid

What is Trichloroisocyanuric Acid?

Trichloroisocyanuric Acid (SYMCLOSENE) is a Small molecule drug.

How does Trichloroisocyanuric Acid work?

Trichloroisocyanuric Acid works by releasing chlorine gas when it comes into contact with water, which then kills bacteria and other microorganisms.

What is the generic name of Trichloroisocyanuric Acid?

SYMCLOSENE is the generic (nonproprietary) name of Trichloroisocyanuric Acid.

What development phase is Trichloroisocyanuric Acid in?

Trichloroisocyanuric Acid is in Phase 2.

Therapeutic area: All drugs in Infectious Disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing